Pinnacle Summer Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Pinnacle Summer Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$41K	Buy	+215	New	+$37.6K	0.01%	370

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pinnacle Summer Investments's ALXN Position: Q4 2015 in Review

Pinnacle Summer Investments opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2015: 215 shares worth $41K. The stake represents 0.01% of the portfolio and ranks #370 among its holdings.

547 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

Pinnacle Summer Investments held 215 shares of Alexion Pharmaceuticals worth $41K as of Q4 2015.
Alexion Pharmaceuticals was a new Pinnacle Summer Investments position in Q4 2015.
Alexion Pharmaceuticals made up 0.01% of Pinnacle Summer Investments's portfolio in Q4 2015, its #370 holding.
547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Pinnacle Summer Investments's 13F filing for Q4 2015, filed 16 Feb 2016.